Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Knockdown of Gls1 increased the expression of Cdkn1a and Cdkn1b and decreased the expression of some critical oncogenes for cancer cell survival, such as c-Myc, Cdk4, and NfκB, as well as some genes which are essential for MM cell survival, such as Irf4, Prdm1, Csnk1α1, and Rassf5.
|
31666930 |
2019 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, high expression levels of cereblon (CRBN) and MUM1 have been associated with better response rates in multiple myeloma treated with lenalidomide.
|
28833354 |
2018 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
|
30213928 |
2018 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recently, we demonstrated that miR-210 was upregulated in hypoxia and downregulated IRF4, which is known as an essential factor in myeloma oncogenesis in normoxia.
|
29444873 |
2018 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, we discuss current therapies for MM as well as direct targeting of IRF4 as a potential new therapeutic strategy.
|
30098518 |
2018 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Given that direct IRF4 inhibitors are clinically unavailable, we intended to explore the mechanism by which IRF4 expression was regulated in MM.
|
29317217 |
2018 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell survival and involved in the regulation of MYC transcription.
|
28751557 |
2017 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Although IRF4/MUM1 expression is associated with aggressiveness of B-cell lymphoma and multiple myeloma, the prognostic value of IRF4/MUM1 expression in peripheral T-cell lymphoma (PTCL) is unclear.
|
28529614 |
2017 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
|
28164410 |
2017 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results for the first time indicate that a crosstalk between IRF4 and Th17 cells is associated with MM prognosis, and IRF4 may be served an important target for MM immunotherapy.
|
29156727 |
2017 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibiting this pathway leads to downregulation of integrins and IRF4, a known myeloma survival factor.
|
29296880 |
2017 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.
|
28052011 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For AL amyloidosis, single nucleotide polymorphisms (SNPs) at 10 loci showed evidence of an association at P<10<sup>-5</sup> with homogeneity of results from the 3 sample sets; some of these were previously documented to influence MM risk, including the SNP at the IRF4 binding site.
|
28025584 |
2017 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival.
|
28643330 |
2017 |
Multiple Myeloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM.
|
28083618 |
2016 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These findings implicate IRF4-mediated CDCA7L expression in MM biology and indicate how germline variation might confer susceptibility to MM.
|
27882933 |
2016 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicate that the KDM3A-KLF2-IRF4 pathway plays an essential role in MM cell survival and homing to the bone marrow, and therefore represents a therapeutic target.
|
26728187 |
2016 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
|
27223072 |
2016 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we found that the anti-MM activity of miR-125b-5p was mediated via direct downregulation of IRF4 and its downstream effector BLIMP-1.
|
25987254 |
2015 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, MICA expression was enhanced in IRF4-silenced cells, indicating a specific suppressive role of this transcription factor on MICA gene expression in MM cells.Taken together, these findings describe novel molecular pathways involved in the regulation of MICA and PVR/CD155 gene expression and identify the transcription factors IKZF-1/IKZF-3 and IRF4 as repressors of these genes in MM cells.
|
26269456 |
2015 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
|
26196464 |
2015 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Interferon Regulatory Factor 4 (IRF4) gene encodes a transcription factor important for key developmental stages of hematopoiesis, with known oncogenic implications in multiple myeloma, adult leukemias and lymphomas.
|
23977280 |
2013 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
One of the downstream targets of CRBN identified is interferon regulatory factor 4 (IRF4), which is critical for myeloma cell survival and is down-regulated by IMiD treatment.
|
22966948 |
2013 |
Multiple Myeloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
|
23992230 |
2013 |
Multiple Myeloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Silencing IRF4 in myeloma cell lines could inhibit myeloma cells proliferation and induce myeloma cell apoptosis, partly by JNK/Jun pathway.
|
23666852 |
2013 |